Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants
JAMA Pediatrics · 01.11.2023 · 177 (11) · 1158
DOI: 10.1001/jamapediatrics.2023.3849 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift JAMA Pediatrics, erschienen am 01.11.2023. Verfasst von Yuting Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Enterocolitis, Necrotizing, Probiotics, Sepsis. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Neonatologie
Abstract (Originalsprache)
Importance Modulation of intestinal microbiome by administering probiotics, prebiotics, or both may prevent morbidity and mortality in premature infants.
Objective
To assess the comparative effectiveness of alternative prophylactic strategies through a network meta-analysis (NMA) of randomized clinical trials. Data Sources MEDLINE, EMBASE, Science Citation Index Expanded, CINAHL, Scopus, Cochrane CENTRAL, and Google Scholar from inception until May 10, 2023. Study Selection Eligible trials tested probiotics, prebiotics, lactoferrin, and combination products for prevention of morbidity or mortality in preterm infants. Data Extraction and Synthesis A frequentist random-effects model was used for the NMA, and the certainty of evidence and inferences regarding relative effectiveness were assessed using the GRADE approach. Main Outcomes and Measures All-cause mortality, severe necrotizing enterocolitis, culture-proven sepsis, feeding intolerance, time to reach full enteral feeding, and duration of hospitalization.
Results
A total of 106 trials involving 25 840 preterm infants were included. Only multiple-strain probiotics were associated with reduced all-cause mortality compared with placebo (risk ratio [RR], 0.69; 95% CI, 0.56 to 0.86; risk difference [RD], −1.7%; 95% CI, −2.4% to −0.8%). Multiple-strain probiotics alone (vs placebo: RR, 0.38; 95% CI, 0.30 to 0.50; RD, −3.7%; 95% CI, −4.1% to −2.9%) or in combination with oligosaccharides (vs placebo: RR, 0.13; 95% CI, 0.05 to 0.37; RD, −5.1%; 95% CI, −5.6% to −3.7%) were among the most effective interventions reducing severe necrotizing enterocolitis. Single-strain probiotics in combination with lactoferrin (vs placebo RR, 0.33; 95% CI, 0.14 to 0.78; RD, −10.7%; 95% CI, −13.7% to −3.5%) were the most effective intervention for reducing sepsis. Multiple-strain probiotics alone (RR, 0.61; 95% CI, 0.46 to 0.80; RD, −10.0%; 95% CI, −13.9% to −5.1%) or in combination with oligosaccharides (RR, 0.45; 95% CI, 0.29 to 0.67; RD, −14.1%; 95% CI, −18.3% to −8.5%) and single-strain probiotics (RR, 0.61; 95% CI, 0.51 to 0.72; RD, −10.0%; 95% CI, −12.6% to −7.2%) proved of best effectiveness in reduction of feeding intolerance vs placebo. Single-strain probiotics (MD, −1.94 days; 95% CI, −2.96 to −0.92) and multistrain probiotics (MD, −2.03 days; 95% CI, −3.04 to −1.02) proved the most effective in reducing the time to reach full enteral feeding compared with placebo. Only single-strain and multistrain probiotics were associated with greater effectiveness compared with placebo in reducing duration of hospitalization (MD, −3.31 days; 95% CI, −5.05 to −1.58; and MD, −2.20 days; 95% CI, −4.08 to −0.31, respectively). Conclusions and Relevance In this systematic review and NMA, moderate- to high-certainty evidence demonstrated an association between multistrain probiotics and reduction in all-cause mortality; these interventions were also associated with the best effectiveness for other key outcomes. Combination products, including single- and multiple-strain probiotics combined with prebiotics or lactoferrin, were associated with the largest reduction in morbidity and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
- Department of Pediatrics, University of Antioquia, Medellin, Colombia.
- Pediatric Intensive Care Unit, Clínica Las Americas-AUNA, Medellin, Colombia.
- School of Medicine, Case Western Reserve University, Cleveland, Ohio.
- Ted Rogers Centre for Heart Research, University Health Network, Toronto, Ontario, Canada.
- Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada.
Zitieren
APA
Wang, Y., Florez, I. D., Morgan, R. L., Foroutan, F., Chang, Y., Crandon, H. N., Zeraatkar, D., Bala, M. M., Mao, R. Q., Tao, B., Shahid, S., Wang, X., Beyene, J., Offringa, M., Sherman, P. M., El Gouhary, E., Guyatt, G. H., & Sadeghirad, B. (2023). Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants. JAMA Pediatrics, 177(11), 1158. https://doi.org/10.1001/jamapediatrics.2023.3849
Vancouver
Wang Y, Florez ID, Morgan RL, Foroutan F, Chang Y, Crandon HN, et al. Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants. JAMA Pediatrics. 2023;177(11):1158. doi:10.1001/jamapediatrics.2023.3849
BibTeX
@article{Wang2023,
author = {Wang, Yuting and Florez, Ivan D and Morgan, Rebecca L and Foroutan, Farid and Chang, Yaping and Crandon, Holly N and Zeraatkar, Dena and Bala, Malgorzata M and Mao, Randi Q and Tao, Brendan and Shahid, Shaneela and Wang, Xiaoqin and Beyene, Joseph and Offringa, Martin and Sherman, Philip M and El Gouhary, Enas and Guyatt, Gordon H and Sadeghirad, Behnam},
title = {Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants},
journal = {JAMA Pediatrics},
year = {2023},
volume = {177},
number = {11},
pages = {1158},
doi = {10.1001/jamapediatrics.2023.3849}
}
EUVIMED